Skip to Content
Merck
HomeBacteriologyLipopolysaccharides

Lipopolysaccharides

Synonym: LPS

Product Information

Lipopolysaccharides (LPS) are characteristic components of the cell wall of Gram negative bacteria; they are not found in Gram positive bacteria. They are localized in the outer layer of the membrane and are, in noncapsulated strains, exposed on the cell surface. They contribute to the integrity of the outer membrane, and protect the cell against the action of bile salts and lipophilic antibiotics.1

Lipopolysaccharides are made up of a hydrophobic lipid (lipid A, which is responsible for the toxic properties of the molecule), a hydrophilic core polysaccharide chain, and a hydrophilic O-antigenic polysaccharide side chain. In most cases, O-specific chains are built of repeating units of oligosaccharides which exhibit a strain-specific structural diversity. The sugar constituents, their sequence, and their mode of linkage determine the serological O specificity of respective strains. They are the main determinants of the classifications of the serotypes of Salmonella species. The diversity of O chains in Enterobacteriaceae may have developed during evolution to allow enteric bacteria to escape the host’s immune system by developing new specificities on their cell surface (specific to the bacterial serotype).1

Since lipopolysaccharides confer antigenic properties on the cell, they have been termed O antigens. As the main antigen, lipopolysaccharides are involved in various host-parasite interactions. They seem to protect Gram negative bacteria from phagocytosis and lysis.1 Bacteria with common serotypes have surface antigens (group O, group H, or LPS) which generate the same antibody response. Examples of serotypes are O55:B5 and O26:B6 for the E. coli bacterium. The designations are immunological classifications, which specify which antibody recognized which strains. Different strains may have some common antigenic determinants.

If a wild strain of bacterium is irradiated with UV light or exposed to mutagenic compounds, it will mutate. The few mutations that are not lethal result in viable mutants (rough strains) which are generally not found in nature, and which possess some unique characteristics. The genes that encode lipopolysaccharide formation may also be altered in the mutants, and LPS with shorter polysaccharide chains may be formed. Ra, Rb, Rc, Rd, Re, etc. (where a, b, c, etc... designate 1st, 2nd, 3rd, etc... degree, respectively) designate the polysaccharide length of a given LPS. Ra and Re designate the mutants with the longest and shortest chain lengths, respectively.2 The most extreme mutants are the Re mutants which produce an LPS which is made up of Lipid A and 3-deoxy-D-manno-octulosonic acid (2-Keto-3-deoxyoctonate, KDO) as the sole constituent of the core.2 Lipid A and lipopolysaccharides from rough strains are tested for KDO content.3

Purified endotoxin is generally referred to as lipopolysaccharide or LPS, to distinguish it from the more natural complexed cell membrane associated form. The core portion of the polysaccharide chain is common to LPS from wild and mutant bacterial strains.

Removal by hydrolysis of the polysaccharide chain from LPS produces lipid A, either as the naturally occurring, cytotoxic diphosphoryl form4 or the less toxic, monophosphoryl form.5,6 The longer the polysaccharide chain is, the longer and more difficult the hydrolysis. LPS with a long polysaccharide chain has a relatively low lipid A content, which must be purified from a large amount of hydrolysis byproducts (oligosaccharides and saccharide monomers). Thus, the yield of lipid A is low and recovery is poor. LPS with a short polysaccharide chain (LPS from mutant bacteria) is therefore used to produce lipid A products. Removal of the fatty acid portions of lipid A results in a detoxified LPS7 with an endotoxin level about 10,000 times lower than that of the parent LPS.

The molecular structure of LPS has been studied.8,9 Since LPS is heterogeneous and tends to form aggregates of varying sizes, the molecular weight is not very meaningful. However, there is a reported range of 1-4 million or greater. When the LPS is treated with SDS and heat, the molecular weight is in the range of 50 to 100 kDa. In their purest form, in the presence of strong surface active agents, and in the absence of divalent cations, bacterial endotoxins consist of 10-20 kDa macromolecules. In the absence of surface active agents and in the presence of divalent cation sequestering agents such as EDTA, LPS is believed to arrange itself into a micellar structure with a molecular weight of approximately 1,000 kDa. This is the smallest form of bacterial LPS that is likely to exist in aqueous liquids. In the presence of divalent cations such as Ca2+ and Mg2+, a bilayer structure appears to exist that passes through a 0.2 μm membrane, but does not pass through a 0.025 μm membrane. LPS vesicles up to 0.1 μm in diameter may also be formed in water in the presence of divalent cations. The self aggregation of LPS is generally a function of the lipid A component of the molecule, which also confers the ability to bind to hydrophobic surfaces.

LPS can be prepared by TCA,10 phenol,11 or phenolchloroform- petroleum ether (for rough strains)12 extraction. The TCA extracted lipopolysaccharides are structurally similar to the phenol extracted ones. Their electrophoretic pattern and endotoxicity are similar. The main differences are in the amounts of nucleic acid and protein contaminations. The TCA extract contains approximately 2% RNA and approximately 10% denatured proteins. The phenol extract contains up to 60% RNA and less than 1% protein. Purification by gel filtration chromatography removes much of protein present in the phenol-extracted LPS, but leaves a product that still contains 10-20% nucleic acids. Further purification using ion exchange chromatography, will yield an LPS product which contains <1% protein and <1% RNA. We offer LPS with various levels of protein and/or RNA.

Our lipopolysaccharides contain endotoxin levels of not less than 500,000 EU (endotoxin units)/mg unless otherwise noted. One nanogram of endotoxin is equivalent to 0.5 EU in 1 ng of material if you have 500,000 EU/mg (Limulus lysate assay) and 10 EU (chromogenic assay).

LPS preparations are used extensively for research in the elucidation of LPS structure,13 metabolism,14 immunology,15 physiology,16 toxicity,17 and biosynthesis.18 They have also been used to induce synthesis and secretion of growth promoting factors such as interleukins.19

FITC (fluorescein isothiocyanate), TRITC (tetramethyrhodamine isothiocyanate), and TNP (trinitrophenyl) conjugates have been prepared by reacting LPS with either FITC, TRITC or 2,4,6-trinitrobenzenesulfonic acid, respectively.20 They are used in research on the T-independent B cell immune response to bacterial LPS.20

Precautions and Disclaimer

For Laboratory Use Only. Not for drug, household or other uses.

Storage/Stability

Solutions at 1 mg/mL in buffer or culture medium are stable for approximately one month at 2-8 °C. Frozen aliquots can be stored up to 2 years. Repeated freeze/thaw cycles are not recommended. Solutions should be stored in silanized containers, since LPS can bind to plastics and certain types of glass (especially at concentrations of <0.1 mg/mL). If the LPS concentration is >1 mg/mL, adsorption to the sides of the vial is negligible. If glass containers are used, solutions should be vortexed for at least 30 minutes to redissolve the adsorbed product.

Preparation Instructions

The product is soluble in water (5 mg/mL) or cell culture medium (1 mg/mL) yielding a hazy, faint yellow solution. A more concentrated, though still hazy, solution (20 mg/mL) has been achieved in aqueous saline after vortexing and warming to
70-80 °C.21 Lipopolysaccharides are molecules that form micelles in every solvent. Hazy solutions are observed in water and phosphate buffered saline. Organic solvents do not give clearer solutions. Methanol yields a turbid suspension with floaters, while water yields a homogeneously hazy solution.

For cell culture use, LPS should be reconstituted by adding 1 mL of sterile balanced salt solution or cell culture medium to a
vial (1 mg) and swirling gently until the powder dissolves. Solutions can be further diluted to the desired working concentration with additional sterile balanced salt solutions or cell culture media.

LPS Table

* = discontinued product number
Ph/Chl/Pet = phenol:chloroform:petroleum ether

References

1.
Mayer H, Tharanathan R, Weckesser J. 1985. 6 Analysis of Lipopolysaccharides of Gram-Negative Bacteria.157-207. https://doi.org/10.1016/s0580-9517(08)70475-6
2.
Raetz CRH. 1990. Biochemistry of Endotoxins. Annu. Rev. Biochem.. 59(1):129-170. https://doi.org/10.1146/annurev.bi.59.070190.001021
3.
CYNKIN MA, ASHWELL G. 1960. Estimation of 3-Deoxy Sugars by Means of the Malonaldehyde?Thiobarbituric Acid Reaction. Nature. 186(4719):155-156. https://doi.org/10.1038/186155a0
4.
Qureshi N, Takayama K, Heller D, Fenselau C. 1983. Position of ester groups in the lipid A backbone of lipopolysaccharides obtained from Salmonella typhimurium. J Biol Chem. 258(21):12947-51.
5.
Chang C, Nowotny A. 1975. Relation of structure to function in bacterial O-antigens?VII. Endotoxicity of ?lipid A?. Immunochemistry. 12(1):19-28. https://doi.org/10.1016/0019-2791(75)90045-2
6.
Qureshi N, Takayama K, Ribi E. 1982. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 257(19):11808-15.
7.
Ding HF, Nakoneczna I, Hsu HS. 1990. Protective immunity induced in mice by detoxified salmonella lipopolysaccharide. Journal of Medical Microbiology. 31(2):95-102. https://doi.org/10.1099/00222615-31-2-95
8.
JANN B, RESKE K, JANN K. 1975. Heterogeneity of Lipopolysaccharides. Analysis of Polysaccharide Chain Lengths by Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis. Eur J Biochem. 60(1):239-246. https://doi.org/10.1111/j.1432-1033.1975.tb20996.x
9.
Leive L, Morrison DC. 1972. [23] Isolation of lipopolysaccharides from bacteria.254-262. https://doi.org/10.1016/0076-6879(72)28025-9
10.
Staub A. 1965. Bacterial Lipido-protinopolysaccharides (‘O’ Somatic Antigens) Extraction with Trichloroacetic Acid. Methods in Carbohydrate Chem. 592-93.
11.
Westphal O, Jann K. 1965. Bacterial Lipopolysaccharides Extraction with Phenol-Water and Further Applications of the Procedure. Methods in Carbohydrate Chem. 583-91.
12.
Galanos C, Luderitz O, Westphal O. 1969. A New Method for the Extraction of R Lipopolysaccharides. Eur J Biochem. 9(2):245-249. https://doi.org/10.1111/j.1432-1033.1969.tb00601.x
13.
Strain S, Fesik S, Armitage I. 1983. Characterization of lipopolysaccharide from a heptoseless mutant of Escherichia coli by carbon 13 nuclear magnetic resonance. J Biol Chem. 258(2):2906-10.
14.
Munford RS, Andersen JM, Dietschy JM. 1981. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey.. J. Clin. Invest.. 68(6):1503-1513. https://doi.org/10.1172/jci110404
15.
Morrison DC, Rudbach JA. 1981. Endotoxin-Cell-Membrane Interactions Leading to Transmembrane Signaling.187-218. https://doi.org/10.1007/978-1-4684-3917-5_6
16.
Goodwin T. 1977. Biochemistry of Lipids II. Baltimore: Univeristy Park Press.
17.
Kurtz H, Quast J. 1982. Effects of continuous intravenous infusion of Escherichia coli endotoxin into swine. Am J Vet Res. 43(2):262-8.
18.
Rick PD, Young DA. 1982. Isolation and characterization of a temperature-sensitive lethal mutant of Salmonella typhimurium that is conditionally defective in 3-deoxy-D-manno-octulosonate-8-phosphate synthesis.. 150(2):447-455. https://doi.org/10.1128/jb.150.2.447-455.1982
19.
Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. 1986. There is more than one interleukin 1. Immunology Today. 7(2):45-56. https://doi.org/10.1016/0167-5699(86)90124-6
20.
Skelly RR, Munkenbeck P, Morrison DC. 1979. Stimulation of T-independent antibody responses by hapten-lipopolysaccharides without repeating polymeric structure.. 23(2):287-293. https://doi.org/10.1128/iai.23.2.287-293.1979
21.
Customer Report.
22.
Fomsgaard A, Freudenberg MA, Bendtzen K, Galanos C. 1990. Quantitation and biological activities of native tumour necrosis factor from LPS-stimulated human monocytes. 98(1-6):529-534. https://doi.org/10.1111/j.1699-0463.1990.tb01067.x
23.
Bleicher P, Rollins-Smith LA, Jacobs DM, Cohen N. 1983. Mitogenic responses of frog lymphocytes to crude and purified preparations of bacterial lipopolysaccharide (LPS). Developmental & Comparative Immunology. 7(3):483-496. https://doi.org/10.1016/0145-305x(83)90033-2
24.
Sveen K, Skaug N. 1992. Comparative mitogenicity and polyclonal B cell activation capacity of eight oral or nonoral bacterial lipopolysaccharides in cultures of spleen cells from athymic (nu/nu-BALB/c) and thymic (BALB/c) mice. Oral Microbiol Immunol. 7(2):71-77. https://doi.org/10.1111/j.1399-302x.1992.tb00512.x
25.
Hepper K, Garman RD, Lyons MF, Teresa GW. 1979. Plaque-forming cell response in BALB/c mice to two preparations of LPS extracted from Salmonella enteritidis. J Immunol. 122(4):1290-3.
26.
Gardiner JS, Keil LB, DeBari VA. 1991. In vitro Formation of Complement Activation Products by Lipopolysaccharide Chemotypes of Salmonellaminnesota. Int Arch Allergy Immunol. 96(1):51-54. https://doi.org/10.1159/000235534
27.
Salter M, Knowles RG, Moncada S. 1991. Widespread tissue distribution, species distribution and changes in activity of Ca2+-dependent and Ca2+-independent nitric oxide synthases. 291(1):145-149. https://doi.org/10.1016/0014-5793(91)81123-p
28.
Mond JJ, Brunswick M. 2003. Proliferative Assays for B Cell Function. Current Protocols in Immunology. 57(1): https://doi.org/10.1002/0471142735.im0310s57
29.
Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang SC, Nakayama DK, Simmons RL, Snyder SH, Billiar TR. 1993. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes.. Proceedings of the National Academy of Sciences. 90(8):3491-3495. https://doi.org/10.1073/pnas.90.8.3491
30.
Wrenger E, Baumann C, Behrend M, Zamore E, Schindler R, Brunkhorst R. 1998. Peritoneal mononuclear cell differentiation and cytokine production in intermittent and continuous automated peritoneal dialysis. American Journal of Kidney Diseases. 31(2):234-241. https://doi.org/10.1053/ajkd.1998.v31.pm9469493
31.
Hawkins D, MacKay R, MacKay S, Moldawer L. 1998. Human interleukin 10 suppresses production of inflammatory mediators by LPS-stimulated equine peritoneal macrophages. Veterinary Immunology and Immunopathology. 66(1):1-10. https://doi.org/10.1016/s0165-2427(98)00181-0
32.
Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, Springer TA, Gutierrez-Ramos JC. 1994. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice.. 180(1):95-109. https://doi.org/10.1084/jem.180.1.95
33.
Stuehr DJ, Marletta MA. 1985. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide.. Proceedings of the National Academy of Sciences. 82(22):7738-7742. https://doi.org/10.1073/pnas.82.22.7738
34.
Wang J, Kester M, Dunn MJ. 1988. The effects of endotoxin on platelet-activating factor synthesis in cultured rat glomerular mesangial cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 969(3):217-224. https://doi.org/10.1016/0167-4889(88)90055-9
35.
Cassatella MA, Bazzoni F, Flynn RM, Dusi S, Trinchieri G, Rossi F. 1990. Molecular basis of interferon-gamma and lipopolysaccharide enhancement of phagocyte respiratory burst capability. Studies on the gene expression of several NADPH oxidase components. J Biol Chem. 265(33):20241-6.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?